Contineum Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 35.48 percent increase over losses of $(0.62) per
Contineum lost less money per share than experts thought it would, which is good news. When a company doing research loses money slower than expected, it might mean their plan is working better than people feared.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.